CMTM1 Antibody

What is CMTM1 and what is its biological significance?

CMTM1 (CKLF-like MARVEL transmembrane domain-containing protein 1), also known as CKLFSF1 (Chemokine-like factor superfamily member 1), is a 169 amino acid multi-pass membrane protein that belongs to the chemokine-like factor superfamily. The protein contains a CC-chemokine motif and four transmembrane segments. The gene encoding CMTM1 resides in a tight gene cluster on human chromosome 16 with CKLF, CMTM2, CMTM3, and CMTM4 . There are at least sixteen isoforms of CMTM1 that are produced as a result of alternative splicing events. CMTM1 is highly expressed in testis, suggesting a role in spermatogenesis or testicular development . Recent research has also implicated CMTM1 in cancer biology, particularly in hepatocellular carcinoma (HCC), where its expression has been associated with patient prognosis .

What are the primary applications for CMTM1 antibodies in research?

CMTM1 antibodies are utilized across numerous experimental techniques:

These applications are essential for studying CMTM1's expression patterns, cellular localization, and potential involvement in disease processes. For immunofluorescence applications specifically, antibodies like ab196804 have been used at 1:100 dilution in MCF7 cells with successful visualization of the protein .

How can I select the appropriate CMTM1 antibody for my research needs?

Selection should be based on:

• Target region specificity: Different antibodies target various regions of CMTM1:

  • C-terminal region antibodies

  • Full-length protein antibodies (AA 1-286)

  • Specific peptide sequence antibodies

• Validated applications: Confirm that the antibody has been validated for your intended application (IHC, WB, IF, ELISA) .

• Species reactivity: Most commercially available CMTM1 antibodies are reactive with human samples .

• Clonality considerations: Most available CMTM1 antibodies are polyclonal, derived from rabbit hosts .

• Isoform detection: Consider which of the 16 potential CMTM1 isoforms you need to detect, as different antibodies may recognize different isoforms .

What validation data should I look for when selecting a CMTM1 antibody?

Thorough validation information should include:

• Application-specific data: Look for actual experimental images showing the antibody performance in your application of interest.

• Knockout/knockdown validation: Confirmation that signal is reduced/absent in samples where CMTM1 expression has been experimentally diminished.

• Peptide competition assays: Evidence that the signal can be blocked by pre-incubation with the immunizing peptide, as demonstrated with antibody ab196804 .

• Positive control tissues: Data showing appropriate staining in tissues known to express CMTM1 (e.g., testis tissue) .

• Expected molecular weight confirmation: Western blot data showing bands at the expected molecular weight.

How do I optimize immunohistochemistry protocols for CMTM1 detection in tissue samples?

Based on published methodologies for CMTM1 detection in HCC and other tissues :

• Tissue preparation:

  • Fix tissues in formalin and embed in paraffin

  • Section tissues at approximately 2 microns thickness

• Antigen retrieval:

  • Heat-induced epitope retrieval in EDTA buffer (pH 8.0)

  • Process under high pressure and heat for approximately 2.5 minutes

• Blocking strategy:

  • Block endogenous peroxidase activity (10-minute treatment)

  • Apply goat serum for 20 minutes to reduce non-specific binding

• Antibody incubation:

  • Primary antibody: Incubate overnight at 4°C

  • Secondary antibody: Incubate for 30 minutes at room temperature

• Signal assessment scheme:

  • Score percentage of positively stained cells:

    • 0 for ≤5%

    • 1 for 6–25%

    • 2 for 26–50%

    • 3 for 51–75%

    • 4 for >75%

  • Score intensity of staining:

    • 0 for uncolored

    • 1 for light yellow

    • 2 for brown

    • 3 for yellow-brown

  • Calculate final score by multiplying these values:

    • 0 = negative (-)

    • 1-4 = weakly positive (+)

    • 5-8 = moderately positive (++)

    • 9-12 = strongly positive (+++)

How can I resolve conflicting data between mRNA and protein expression levels of CMTM1?

Research on CMTM1 in HCC has revealed interesting discrepancies between mRNA and protein expression :

• Acknowledge methodological differences:

  • Bioinformatics analyses of mRNA from databases like TCGA may use different samples than IHC-based protein studies

  • RNA sequencing provides transcriptome-wide quantification while IHC provides localized protein detection

• Consider post-transcriptional regulation:

  • Implement parallel qRT-PCR and Western blot/IHC analyses on the same samples

  • Investigate miRNAs that may regulate CMTM1 translation

  • Examine protein stability and turnover rates in your specific cellular context

• Design validation experiments:

  • Confirm mRNA findings with multiple primer sets targeting different CMTM1 exons

  • Validate protein expression with multiple antibodies targeting different epitopes

  • Complement IHC with Western blot analysis for quantitative comparison

• Analyze isoform complexity:

  • The 16 known isoforms of CMTM1 may show differential expression patterns

  • Some antibodies may recognize only specific isoforms

  • Design isoform-specific primers for RNA analysis

• Case study from HCC research:

  • Bioinformatics analysis showed elevated CMTM1 mRNA in HCC tissues compared to normal liver

  • IHC showed similar CMTM1 protein positivity rates in HCC (84%) and adjacent non-tumor tissues (89.3%)

  • This discrepancy may be explained by tissue source differences, tumor heterogeneity, or post-transcriptional regulation

What is the evidence for CMTM1's role in cancer progression and how can antibodies help elucidate its function?

Evidence from recent research reveals complex roles for CMTM1 in cancer:

Research approaches using antibodies to investigate CMTM1 function:

• Expression profiling:

  • Use IHC with CMTM1 antibodies to analyze expression across tissue microarrays

  • Correlate expression patterns with clinical outcomes and tumor characteristics

  • Example: CMTM1 expression correlation with family history and TNM stage in HCC

• Mechanistic studies:

  • Use antibodies for immunoprecipitation to identify protein interaction partners

  • Perform ChIP assays to investigate transcriptional regulation

  • Apply immunofluorescence to examine subcellular localization changes during disease progression

• Therapeutic potential investigation:

  • Develop function-blocking antibodies targeting extracellular domains

  • Test antibody-drug conjugates if CMTM1 shows tumor-specific expression

  • Use antibodies to monitor CMTM1 expression changes in response to treatments

How can I distinguish between different CMTM1 isoforms in my experimental system?

With at least 16 reported isoforms of CMTM1 , isoform-specific detection is challenging but essential:

• RNA-level discrimination:

  • Design PCR primers spanning unique exon junctions of specific isoforms

  • Use droplet digital PCR for absolute quantification of low-abundance isoforms

  • Employ RNA-seq with appropriate bioinformatic pipelines to distinguish isoform-specific reads

• Protein-level discrimination:

  • Select antibodies whose epitopes are present or absent in specific isoforms

  • Use epitope mapping to determine which isoforms are recognized by available antibodies

  • Separate isoforms by molecular weight using high-resolution gel electrophoresis before Western blotting

• Functional validation:

  • Create expression constructs for individual isoforms to serve as positive controls

  • Develop isoform-specific knockdown strategies

  • Use mass spectrometry to identify and quantify isoform-specific peptides

• Experimental considerations for CMTM1-v17:

  • This specific isoform has distinct functions in prostate tissues as an androgen receptor co-inhibitor

  • Develop validation assays using prostate cell lines that express this isoform

  • Consider co-immunoprecipitation experiments with androgen receptor antibodies

How can I troubleshoot non-specific binding when using CMTM1 antibodies in immunofluorescence?

When encountering non-specific binding:

• Optimize blocking conditions:

  • Test different blocking reagents (BSA, normal serum, commercial blockers)

  • Increase blocking duration (1-2 hours at room temperature)

  • Include protein in antibody dilution buffers (0.1-1% BSA)

• Antibody dilution optimization:

  • Perform titration experiments to determine optimal concentration

  • For CMTM1 antibodies like ab196804, 1:100 has been successfully used in MCF7 cells

  • Consider extended washing steps between antibody incubations

• Peptide competition controls:

  • Run parallel staining with antibody pre-incubated with immunizing peptide

  • This approach has been documented with ab196804, showing specific binding

• Fixation considerations:

  • Test different fixation methods (paraformaldehyde, methanol, acetone)

  • Optimize fixation duration to preserve epitope accessibility

  • Consider mild permeabilization methods for membrane proteins like CMTM1

• Secondary antibody selection:

  • Use highly cross-adsorbed secondary antibodies

  • Test secondary antibody alone to check for direct non-specific binding

  • Consider direct conjugation of primary antibodies for multicolor applications

What methodological approaches can help resolve contradictory findings about CMTM1's prognostic significance in cancer?

The contradictory findings regarding CMTM1's prognostic value in HCC highlight the need for robust methodological approaches:

• Standardize detection methods:

  • Employ the same antibody clones and standardized protocols across studies

  • Use automated staining platforms to reduce technical variability

  • Implement digital pathology for objective quantification

• Patient stratification refinement:

  • Analyze CMTM1 expression in relation to molecular subtypes of cancer

  • Control for treatment history and other clinical variables

  • Increase cohort sizes to improve statistical power

• Integrative multi-omics approach:

  • Correlate protein expression with genomic and transcriptomic data

  • Investigate epigenetic regulation of CMTM1

  • Examine post-translational modifications that may affect function

• Functional validation studies:

  • Develop in vitro systems that recapitulate clinical phenotypes

  • Test the impact of CMTM1 modulation on cancer cell properties

  • Create animal models with controlled CMTM1 expression

• Meta-analysis methodology:

  • Pool data from multiple studies with appropriate statistical methods

  • Account for differences in antibodies, scoring systems, and cut-offs

  • Address the potential impact of publication bias

How should I design multiplex immunofluorescence panels that include CMTM1?

For effective multiplex staining:

• Panel design principles:

  • Pair CMTM1 antibodies with markers of relevant biological pathways

  • Consider subcellular localization when selecting fluorophores

  • Include appropriate controls for each antibody in the panel

• Technical optimization:

  • Determine optimal staining sequence

  • Test for and mitigate antibody cross-reactivity

  • Validate individual antibodies before combining them

• Example CMTM1 multiplex panel for cancer research:

• Spectral unmixing requirements:

  • Account for fluorophore spectral overlap

  • Establish single-stain controls for unmixing algorithms

  • Consider tissue autofluorescence in channel selection

What are the critical considerations for using CMTM1 antibodies in flow cytometry?

While flow cytometry applications for CMTM1 are not explicitly mentioned in the provided search results, researchers should consider:

• Antibody selection criteria:

  • Choose antibodies that recognize extracellular epitopes if staining live cells

  • For intracellular domains, effective fixation and permeabilization are crucial

  • Verify that the epitope remains accessible after processing

• Protocol optimization:

  • Titrate antibody concentration to determine optimal signal-to-noise ratio

  • Test different fixation and permeabilization reagents

  • Optimize incubation times and temperatures

• Controls for accurate interpretation:

  • Include FMO (fluorescence minus one) controls

  • Use cell lines with known CMTM1 expression levels as positive controls

  • Incorporate isotype controls matched to the CMTM1 antibody

• Multi-parameter considerations:

  • Design panels that include relevant markers to identify cell populations of interest

  • Account for CMTM1's expression in specific cell types (particularly relevant for testicular cell populations)

  • Consider compensation requirements when using multiple fluorophores

How can CMTM1 antibodies be effectively used in protein interaction studies?

To investigate CMTM1's protein interactions:

• Co-immunoprecipitation optimization:

  • Select antibodies that don't interfere with protein binding regions

  • Test different lysis conditions to preserve protein-protein interactions

  • Consider crosslinking approaches for transient interactions

• Proximity ligation assay (PLA) application:

  • Pair CMTM1 antibodies with antibodies against suspected interaction partners

  • Ensure antibodies are raised in different host species

  • Optimize fixation to preserve spatial relationships while maintaining epitope accessibility

• FRET/BRET approaches:

  • Design fusion proteins for live-cell interaction studies

  • Validate that fusion tags don't disrupt CMTM1 localization or function

  • Develop appropriate positive and negative controls

• Potential interaction partners to investigate:

  • Other CMTM family members in the gene cluster (CMTM2, CMTM3, CMTM4)

  • Chemokine receptors (given CMTM1's chemokine-like domain)

  • Androgen receptor (based on CMTM1-v17 isoform interactions)

How might CMTM1 antibodies contribute to understanding the protein's role in immune regulation?

As a member of the chemokine-like factor superfamily, CMTM1 may have immunomodulatory functions:

• Immune cell expression profiling:

  • Use flow cytometry and immunohistochemistry to map CMTM1 expression across immune cell populations

  • Correlate expression with activation states and functional markers

  • Investigate expression changes during immune responses or inflammation

• Functional assays:

  • Develop blocking antibodies to inhibit potential CMTM1 receptor interactions

  • Examine effects on immune cell migration, activation, and cytokine production

  • Test effects in mixed lymphocyte reactions or other immune function assays

• Structural insights:

  • Use antibodies to map functional domains through epitope binning

  • Compare structural relationships to other chemokine family members

  • Investigate how different isoforms might have distinct immune functions

What methodological approaches can help determine if CMTM1 could serve as a therapeutic target in cancer?

Building on the association between CMTM1 and cancer progression :

• Target validation strategies:

  • Perform systematic knockdown/knockout studies in cancer models

  • Correlate expression with therapy resistance phenotypes

  • Develop inducible expression systems to study dosage effects

• Antibody-based therapeutic approaches:

  • Screen for antibodies that modulate CMTM1 function

  • Test antibody-drug conjugates if CMTM1 shows tumor-specific expression

  • Develop bispecific antibodies linking CMTM1 to immune effector cells

• Combination therapy investigations:

  • Evaluate CMTM1 targeting in combination with standard chemotherapies

  • Test with immune checkpoint inhibitors if CMTM1 has immunomodulatory functions

  • Investigate synergy with targeted therapies in specific cancer types

• Biomarker development:

  • Standardize IHC protocols for potential diagnostic use

  • Correlate CMTM1 expression with treatment response

  • Develop quantitative assays for monitoring expression during treatment

The complex role of CMTM1 in HCC prognosis suggests careful consideration of context-dependent functions before therapeutic development.

What are the most significant knowledge gaps in our understanding of CMTM1 biology that antibody-based research could address?

Despite progress in CMTM1 research, several key questions remain:

• Functional mechanisms:

  • How does CMTM1 contribute to normal physiological processes versus pathological states?

  • What are the signaling pathways activated or inhibited by CMTM1?

  • How do the 16 different isoforms differ in their functions?

• Structural biology:

  • What is the detailed three-dimensional structure of CMTM1?

  • How does structure relate to function for different domains?

  • What are the key interaction interfaces with binding partners?

• Cell type-specific roles:

  • Beyond testicular expression, what are CMTM1's functions in other tissue types?

  • How does expression vary across different cell populations within tissues?

  • What regulates tissue-specific expression patterns?

• Disease relevance beyond cancer:

  • Does CMTM1 play roles in inflammatory or immune-mediated diseases?

  • Could CMTM1 be involved in developmental processes or stem cell biology?

  • Are there connections to metabolic disorders or other pathological conditions?

Antibody-based approaches, combined with emerging technologies like spatial transcriptomics and proteomics, will be instrumental in addressing these knowledge gaps.

How can researchers contribute to improving CMTM1 antibody validation standards?

To advance CMTM1 research quality:

• Implement comprehensive validation:

  • Test antibodies in multiple applications (WB, IHC, IF, IP)

  • Validate in CMTM1 knockout/knockdown systems

  • Perform epitope mapping to determine exact binding regions

• Share validation data:

  • Publish detailed antibody validation protocols

  • Deposit validation data in public repositories

  • Report negative results with specific antibody clones

• Address isoform complexity:

  • Characterize which isoforms each antibody recognizes

  • Develop new antibodies targeting isoform-specific regions

  • Create reference materials expressing individual isoforms

• Collaborate on standardization:

  • Establish consensus protocols for CMTM1 detection

  • Develop scoring systems for consistent interpretation

  • Create reference standards for quantitative comparisons